TORNTPHARM - Investment Analysis: Buy Signal or Bull Trap?
Back to ListInvestment Rating: 3.8
| Stock Code | TORNTPHARM | Market Cap | 1,50,267 Cr. | Current Price | 4,446 ₹ | High / Low | 4,714 ₹ |
| Stock P/E | 67.9 | Book Value | 250 ₹ | Dividend Yield | 0.85 % | ROCE | 19.8 % |
| ROE | 27.6 % | Face Value | 5.00 ₹ | DMA 50 | 4,364 ₹ | DMA 200 | 4,027 ₹ |
| Chg in FII Hold | 0.05 % | Chg in DII Hold | -0.09 % | PAT Qtr | 504 Cr. | PAT Prev Qtr | 584 Cr. |
| RSI | 51.7 | MACD | 35.1 | Volume | 3,22,273 | Avg Vol 1Wk | 3,89,389 |
| Low price | 3,140 ₹ | High price | 4,714 ₹ | PEG Ratio | 2.32 | Debt to equity | 1.69 |
| 52w Index | 82.9 % | Qtr Profit Var | 2.49 % | EPS | 64.8 ₹ | Industry PE | 32.1 |
📊 Analysis: TORNTPHARM is fundamentally strong with robust ROE (27.6%) and ROCE (19.8%), highlighting efficient capital usage. EPS (64.8 ₹) supports valuation comfort, but P/E (67.9) is significantly higher than industry average (32.1), suggesting stretched valuations. Dividend yield at 0.85% provides modest returns. Debt-to-equity at 1.69 raises leverage concerns. Current price (4,446 ₹) trades above DMA 50 (4,364 ₹) and DMA 200 (4,027 ₹), reflecting bullish undertone. RSI (51.7) and MACD (35.1) confirm neutral-to-positive momentum. Quarterly PAT declined (584 Cr. → 504 Cr.), showing earnings pressure despite long-term strength.
💰 Entry Zone: Ideal accumulation range lies between 4,300 ₹ – 4,450 ₹, near DMA 50 support, offering valuation comfort before fresh breakout attempts.
📈 Exit Strategy / Holding Period:
If already holding, maintain position for 24–36 months provided EPS growth sustains and ROE remains above 25%. Partial exit near 4,650–4,700 ₹ resistance is prudent if earnings growth does not accelerate. Long-term holding is justified given strong fundamentals, but valuation discipline is essential.
Positive
- 📌 Strong ROE (27.6%) and ROCE (19.8%).
- 📌 EPS at 64.8 ₹ supports valuation comfort.
- 📌 Dividend yield of 0.85% provides steady returns.
- 📌 Institutional confidence with FII holdings up (+0.05%).
- 📌 Strong 52w Index performance (82.9%).
Limitation
- ⚠️ High P/E (67.9) vs industry average (32.1).
- ⚠️ PEG ratio (2.32) suggests growth is expensive relative to valuation.
- ⚠️ Debt-to-equity (1.69) raises leverage risk.
- ⚠️ DII holdings reduced (-0.09%), signaling domestic caution.
- ⚠️ Quarterly PAT declined, showing earnings pressure.
Company Negative News
- 📉 Sequential decline in profitability (584 Cr. → 504 Cr.).
- 📉 Elevated leverage raises sustainability concerns.
Company Positive News
- 📈 EPS remains strong, supporting long-term valuation comfort.
- 📈 Incremental FII holdings reflect foreign investor confidence.
- 📈 Strong sector positioning with consistent demand outlook.
Industry
- 🏭 Industry PE at 32.1 highlights moderate growth expectations.
- 🏭 Pharmaceutical sector benefits from global healthcare expansion.
- 🏭 Competitive pressures remain with large incumbents in generics and specialty drugs.
Conclusion
🔎 TORNTPHARM is fundamentally strong with excellent ROE, ROCE, and EPS, but faces valuation concerns with high P/E and leverage. Entry is favorable near 4,300–4,450 ₹ with strict stop-loss discipline. Long-term investors can hold for 24–36 months, but should reassess if earnings growth does not accelerate. Partial exits near 4,650–4,700 ₹ resistance are prudent.
Would you like me to extend this into a peer benchmarking analysis against Sun Pharma, Cipla, and Dr. Reddy’s, or refine it into a swing trading strategy with short-term entry/exit levels?